AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
_07_17_2023_11_54_00_546595.jpg)
BLS Pharmaceuticals Limited (ASX:BLS) has announced record financial results for the fiscal year ending 30 June 2026, reporting FY26 revenue of $74.98 million alongside a record adjusted EBITDA of $19 million. The company finalized a landmark two-year pharmaceutical supply contract with German firm ADREXpharma valued at approximately $50 million, marking a pivotal step in its global expansion as it evolves into a worldwide pharmaceutical manufacturing and distribution platform.
Key Highlights
- BLS Pharmaceuticals Limited (ASX:BLS), formerly Bioxyne Limited, operates internationally with manufacturing and distribution across Australia, the UK, Germany, and Latin America.
- The company exceeded its FY26 revenue guidance, achieving $74.98 million, representing 156% growth over the previous year and surpassing the forecast range of $65275 million.
- Record adjusted EBITDA reached $19 million, at the upper end of the $16.519 million guidance, with operating cash flow hitting a record $6.3 million in the June quarter.
- BLS secured a $50 million, two-year pharmaceutical supply agreement with Germany's ADREXpharma, including a $25 million minimum commitment in Year 1, and entered the Latin American market with medicinal cannabis exports to Costa Rica.
- Development of the Scotland manufacturing facility remains on track for commissioning by September 2026, supported by A$1.5 million in government loans and grants from South of Scottish Enterprise.
- Cash reserves increased to $13.3 million as of 30 June 2026, coinciding with the company’s rebranding to BLS Pharmaceuticals Limited, reflecting its transformation into a global pharmaceutical manufacturer.
Unprecedented Revenue Growth and FY26 Guidance Surpassed
BLS Pharmaceuticals posted record quarterly revenue of $22.5 million for the quarter ending 30 June 2026, a 5% increase over the previous quarter and the highest quarterly figure in company history. This contributed to full-year FY26 revenue of $74.98 million, positioning the company at the top end of its guidance range of $65275 million and representing a 156% increase compared to the prior fiscal year.
The revenue surge was fueled by strong Australian operations, expanding sales in European markets, growth in white label pharmaceutical manufacturing, and rising demand for regulated therapeutic products. New international commercial agreements further bolstered the financial results, showcasing BLS's ability to drive growth across diverse products and geographies.
Record Adjusted EBITDA and Robust Operating Cash Flow
For FY26, BLS Pharmaceuticals achieved a record adjusted EBITDA of $19 million, marking a 190% increase year-over-year and meeting the top end of its guidance range of $16.519 million. This profitability boost highlights the scalability of BLS's manufacturing platform and the positive impact of revenue growth on operating margins.
In the June quarter, the company reported record positive operating cash flow of $6.3 million, its strongest to date, underscoring operational efficiency and economies of scale. Customer cash receipts totaled $20.7 million for the quarter and $72.9 million for FY26, a 125% increase over FY25.
Strategic Entry into German Market via ADREXpharma Agreement
BLS finalized a significant two-year pharmaceutical supply agreement with Germany’s ADREXpharma GmbH valued at approximately $50 million during the quarter ended 30 June 2026. The contract includes a $25 million minimum purchase commitment in the first year, providing secured revenue visibility.
ADREXpharma holds exclusive rights to distribute BLS’s Dr Watson AE medicinal cannabis portfolio in Germany, Europe’s largest regulated medicinal cannabis market. This exclusive partnership positions BLS to capture a substantial share of the European pharmaceutical cannabis market and validates its manufacturing quality and capabilities.
Expansion into Latin America with Costa Rica Market Entry
BLS achieved its initial commercial entry into Latin America by expanding its supply agreement with Remidose LATAM SRL to provide three Dr Watson AE medicinal cannabis flower products to Costa Rica. The initial sale exceeded $500,000, marking a key milestone in establishing BLS’s presence in the regulated Costa Rican medicinal cannabis sector.
This Latin American expansion reflects BLS’s capability to secure regulatory approvals and commercial partnerships across diverse markets. Management indicated ongoing efforts to pursue further growth opportunities throughout Latin America, signaling a broader regional expansion strategy that diversifies market risk.
Progress on Scotland Manufacturing Facility Enhances UK Market Access
Construction of BLS’s GMP-certified pharmaceutical manufacturing plant in Scotland is progressing on schedule for commissioning by September 2026. Year-to-date capital expenditure reached A$2.1 million, supported by A$1.0 million in loans and A$0.5 million in grants from South of Scottish Enterprise.
The new facility will expand manufacturing capacity and facilitate direct pharmaceutical supply into the UK market, reducing supply chain complexities for customers in the UK and EU. GMP certification ensures compliance with stringent regulatory standards, with commercial production expected to commence in late FY27.
Manufacturing Partnership with Aurora Cannabis and Product Line Expansion
BLS entered a manufacturing agreement with Aurora Cannabis Inc., one of the world’s largest medicinal cannabis companies, to supply GMP-certified medicinal cannabis products. Initial deliveries included over 5,000 units of sublingual oils for Australia and more than 20,000 vape products, with plans to expand into vape products for the UK and German markets.
This partnership underscores BLS’s manufacturing expertise and positions it as a trusted supplier to global pharmaceutical operators. The expanding product range and geographic reach suggest significant revenue potential as the collaboration scales.
Enhanced Board Governance and Corporate Rebranding
During the quarter, BLS appointed Edward Myer as an independent Non-Executive Director, strengthening its governance amid international growth. The company also completed its rebranding from Bioxyne Limited to BLS Pharmaceuticals Limited, reflecting its evolution into a global pharmaceutical manufacturing and distribution entity.
These governance and identity enhancements support BLS’s engagement with international partners and regulators, signaling confidence in its sustained growth trajectory following a record financial year.
Improved Cash Position and Capital Investments
BLS’s cash and cash equivalents rose to $13.3 million at 30 June 2026 from $8.5 million at 31 March 2026, driven by strong operating cash flow and customer receipts. The company also increased inventory levels in anticipation of future demand, representing strategic working capital investment.
Capital expenditures continued to support manufacturing infrastructure and international growth initiatives while maintaining a robust balance sheet. This financial strength enables ongoing expansion of production capacity and market reach.
Transition to Global Pharmaceutical Platform and FY27 Outlook
BLS Pharmaceuticals has transitioned from a domestic cannabis company to an international pharmaceutical manufacturing and distribution platform operating across Australia, the UK, Germany, and Latin America. Its diversified portfolio spans medicinal cannabis, controlled substances, and emerging regulated therapeutics, reducing market concentration risk and positioning the company to capitalize on global growth opportunities.
Management anticipates FY27 will build on FY26’s momentum, supported by a larger international footprint, growing contracted revenues such as the ADREXpharma deal, and a strengthened balance sheet. The Scotland facility commissioning, ongoing European expansion, and Latin American market development are expected to drive further significant revenue and earnings growth in FY27.
